Quick Answer
BioNexus Gene Lab Corp reported R&D Expense of $47.5 thousand for fiscal year 2024.
BioNexus Gene Lab Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $47.5K | -13.6% |
| 2023 | $55.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.9K | +42.5% | +18.5% |
| June 30, 2025 | $12.6K | +53.2% | +3.4% |
| March 31, 2025 | $12.1K | +5.8% | +16.3% |
| September 30, 2024 | $10.4K | — | +27.4% |
| June 30, 2024 | $8.2K | — | -28.6% |
| March 31, 2024 | $11.5K | — | — |
- BioNexus Gene Lab Corp showed a decrease of -13.6% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2024 period, BioNexus Gene Lab Corp’s r&d expense has declined by 13.6% (from $55.0 thousand to $47.5 thousand).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: